Oracle Corp. (NASDAQ:ORCL): UBS’s global survey was generally weak and indicated that Oracle Corp. could beat on earnings, but is unlikely to report revenue upside. Shares are Buy rated with a $36 price target.
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA): After Ariad Pharmaceuticals Inc., completed filing for approval of their Ponatinib drug in the European Union, Stifel Nicolaus increased their target on the company, and cited what they believe to be a reduction of EU regulatory overhang as well as potential for an earlier than expected drug launch there. The firm maintains a Buy rating on the shares.
Bazaarvoice (NYSE:BV): Piper Jaffray views the recent sell-off in shares of Bazaarvoice as unwarranted. They expect the company to report good July quarter results and reaffirm their guidance. The firm reiterates an Overweight rating on their stock with a $21 price target.
Ocz Technology Group Inc. (NASDAQ:OCZ): After the company announced weaker than expected results for their August quarter, Stifel Nicolaus reduced their target on OCZ Technology Group Inc. However, the firm thinks the company’s bookings increased while their PCIe SSD bookings trends appear to be positive. Stifel maintains a Buy rating.
NYSE Euronext, Inc. (NYSE:NYX): UBS said NYSE Euronext, Inc., experienced a broad-based weakness in August, that was seen in all of their businesses, and quarter-to-date volumes were also below their estimates. As a result, the firm lowered their third quarter earnings per share estimates from 50c to 40c and from $2.06 to $1.90 . Shares are Buy rated with a $32 price target.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>